Doctor profile · Federal record

Dr. Daniel Delo, MD

Rheumatology Physician (CMS: Rheumatology) · Wilmington, NC

  • NPI 1114128618
  • Accepts Medicare
  • MIPS 100.0 / 100 · 2023
  • 22 yrs in practice
  • Male
  • Group practice
  • No sanctions

Practice & contact

Operates at 2 locations .

NPPES Updated May 11, 2026
Primary practice
1710 S 17Th St
Wilmington, NC 284016442
(910) 762-1182
fax (910) 762-1291
Additional location
580 S Aiken Ave, Suite 430
Pittsburgh, PA 152321531
(412) 682-2434

Credentials & registration

NPPES · NUCC
NPI registered
May 2007 — 19 yrs on file
Profile last updated
July 21, 2022
Year of graduation
2004 — 22 yrs since
Specialty taxonomy
207RR0500X — NUCC code
State license (1)
North Carolina #2007-00475

Federal sanctions & exclusions

OIG LEIE Updated May 11, 2026

No sanctions, exclusions or revocations on file

Checked against OIG LEIE on NPI 1114128618. Last verified May 11, 2026.

Medicare procedures · 2023

Top services delivered

CMS Provider Utilization
Total services
223,261
Distinct HCPCS
10
Medicare allowed
$3,529,266
HCPCS Description Services Patients Avg allowed
J3262 Injection, tocilizumab, 1 mg 79,040 22 $6
J1602 Injection, golimumab, 1 mg, for intravenous use 38,622 49 $13
J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) 34,800 13 $5
J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) 34,000 61 $42
J3111 Injection, romosozumab-aqqg, 1 mg 13,020 13 $10
J1745 Injection, infliximab, excludes biosimilar, 10 mg 5,760 29 $33
J0897 Injection, denosumab, 1 mg 5,160 56 $23
Q5104 Injection, infliximab-abda, biosimilar, (renflexis), 10 mg 2,930 15 $37
99214 Established patient office or other outpatient visit, 30-39 minutes 1,170 362 $123
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count 1,116 328 $8

In context: peer comparison

Among 5 peers in Wilmington Rheumatology Physician, average services per provider: 1,945. This provider delivers 115× the peer median.

Open Payments

Industry payments received

CMS Open Payments
All-time total
$447
Transactions
22
Manufacturers
12
Payer (manufacturer) Industry Txns Amount
Janssen Biotech, INC. 4 $82.52
Amgen INC. 4 $73.36
Abbvie INC. 3 $69.95
Ucb, INC. 2 $41.36
AstraZeneca Pharmaceuticals Lp 2 $38.46
Novartis Pharmaceuticals Corporation 1 $25.85
Sandoz INC. 1 $23.48
Fresenius Kabi USA, LLC 1 $22.98
Lilly USA, LLC 1 $18.69
Boehringer Ingelheim Pharmaceuticals, INC. 1 $18.42
Aurinia Pharma U.S., INC. 1 $16.05
E.R. Squibb & Sons, L.L.C. 1 $15.87

By nature of payment

Food and Beverage
$447

Medicare Part D · 2023

Top prescriptions

CMS Part D Prescriber
Total claims
1,628
Patients
410
Total drug cost
$416,187
Drug Type Claims Patients Total cost
Methotrexate (Methotrexate Sodium) Brand 343 81 $9,388
Hydroxychloroquine Sulfate Generic 254 59 $12,872
Prednisone Generic 229 71 $2,528
Tramadol Hcl Generic 179 37 $1,868
Alendronate Sodium Generic 101 35 $1,190
Gabapentin Generic 84 28 $1,431
Allopurinol Generic 66 20 $991
Azathioprine Generic 60 20 $3,440
Mycophenolate Mofetil Generic 59 12 $4,431
Celecoxib Generic 58 21 $1,657

Frequently asked questions

Auto-generated from federal data
What is Dr. Daniel Delo's medical specialty?
Dr. Daniel Delo practices Rheumatology Physician in Wilmington, NC.
Where does Dr. Daniel Delo practice?
Dr. Daniel Delo practices at 1710 S 17Th St, Wilmington, NC 284016442. Office phone: 9107621182.
What is Dr. Daniel Delo's NPI?
Dr. Daniel Delo's National Provider Identifier (NPI) is 1114128618, issued by NPPES.
Does Dr. Daniel Delo accept Medicare assignment?
Yes. Dr. Daniel Delo accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Daniel Delo commonly perform?
Top Medicare-reported procedures in 2023: Injection, tocilizumab, 1 mg (HCPCS J3262); Injection, golimumab, 1 mg, for intravenous use (HCPCS J1602); Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (HCPCS J0717). Source: CMS Medicare Physician & Other Practitioners file.